S.Biomedics Past Earnings Performance
Past criteria checks 0/6
There is insufficient data on S.Biomedics's performance over the last few years.
Key information
n/a
Earnings growth rate
n/a
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | n/a |
| Return on equity | -52.6% |
| Net Margin | -57.4% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses BreakdownBeta
How S.Biomedics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 13,108 | -7,524 | 5,590 | 6,508 |
| 30 Sep 23 | 12,549 | -7,306 | 5,204 | 6,613 |
| 30 Jun 23 | 13,790 | -6,809 | 3,752 | 7,426 |
| 31 Mar 23 | 12,825 | -6,987 | 4,408 | 6,039 |
Quality Earnings: A304360 is currently unprofitable.
Growing Profit Margin: A304360 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Unable to establish if A304360's year-on-year earnings growth rate was positive over the past 5 years as it has been trading publicly for less than 3 years.
Accelerating Growth: Unable to compare A304360's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A304360 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A304360 has a negative Return on Equity (-52.63%), as it is currently unprofitable.